MYMD Aug 2024 2.000 call
| Previous close | 0.6100 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.6100 - 0.6100 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireMyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
BALTIMORE, June 17, 2024--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced the appointment of Mitchell Glass, M.D., a member of the board of directors of the Company, as president and chief medical officer. The Company also announced the appointment of Mr. Stephen Friscia, a veteran investor, to the board of di
Business WireMyMD Pharmaceuticals Secures Strategic Investments
BALTIMORE, May 21, 2024--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer
Business WireMyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
BALTIMORE, March 05, 2024--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on March 4, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for co
